Akasi Pharma focuses on developing peptide-based therapeutics aimed at treating peripheral pain conditions.
Akasi Pharma has raised $526K in total funding. The most recent round was Pre-Seed. The last funding was announced in February 2025.
Akasi Pharma's investors include BioInnovation Institute Venture Lab.
Akasi Pharma is headquartered in Copenhagen, Denmark.
Akasi Pharma focuses on developing peptide-based therapeutics aimed at treating peripheral pain conditions.
Akasi Pharma is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Akasi Pharma — Funding & Investors." VCBacked, February 25, 2025, https://www.vcbacked.co/company/akasi-pharma. Accessed September 30, 2026.
VCBacked. (2025). Akasi Pharma — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/akasi-pharma
{{cite web |title=Akasi Pharma — Funding & Investors |url=https://www.vcbacked.co/company/akasi-pharma |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated